Elutia Inc.
ELUTHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeElutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. Valued at $42.0M, ELUT is a micro-cap name in its sector. The company operates in two segments, Women's Health and Cardiovascular.
Market Cap
$42.0M
Beta
0.85
P/E (TTM)
—
P/E (Fwd)
-0.86
EPS (TTM)
$-0.67
EPS (Fwd)
$-1.10
ROE
—
ROA
-26.4%
Cash
$28.5M
Total Debt
$4.2M
Free CF
-$27.0M
52W Change
-54.8%
Annual Financials
Cash vs Debt
Where ELUT stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, ELUT finished 7.14% below its 150-day moving average ($0.98) and 3.19% below its 200-day moving average ($0.94). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ELUT overbought or oversold?
At the July 15, 2026 close, ELUT's RSI(14) was 33.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Elutia Inc. holds $28.5M in cash against $4.2M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$27.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has pulled back from $23.8M (2022) to $12.3M (2025), a 48% decline worth watching.
With cash comfortably exceeding debt, ELUT has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing ELUT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.